uniQure (QURE) CMO sells 30,000 shares and exercises 10,000 stock options

Rhea-AI Filing Summary

uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On June 30, 2026, he sold a total of 30,000 Ordinary Shares in open-market sales at weighted average prices of $46.40 and $46.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.

On the same date, he exercised stock options to acquire 10,000 Ordinary Shares at a $5.59 exercise price, reducing his option position tied to that grant. Following these transactions, he directly owns 148,235 Ordinary Shares and holds 50,500 stock options expiring on March 1, 2034.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares ($1,392,600)

Net Sell 4 txns

Insider Abi-Saab Walid

Role Chief Medical Officer

Sold 30,000 shs ($1.39M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Ordinary Shares	10,000	$5.59	$56K
Sale	Ordinary Shares	10,000	$46.46	$465K
Sale	Ordinary Shares	20,000	$46.40	$928K

Holdings After Transaction: Stock Option (Right to Buy) — 50,500 shares (Direct, null); Ordinary Shares — 178,235 shares (Direct, null)

Footnotes (1)

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.

Key Figures

Shares sold at $46.40: 20,000 shares at $46.40 Shares sold at $46.46: 10,000 shares at $46.46 Options exercised: 10,000 shares at $5.59 +3 more

6 metrics

Shares sold at $46.40 20,000 shares at $46.40 Ordinary Shares sold June 30, 2026

Shares sold at $46.46 10,000 shares at $46.46 Ordinary Shares sold June 30, 2026

Options exercised 10,000 shares at $5.59 Stock options exercised into Ordinary Shares

Shares owned after transactions 148,235 shares Direct Ordinary Share holdings after June 30, 2026

Options remaining 50,500 stock options Options with $5.59 exercise price expiring March 1, 2034

Option expiration date March 1, 2034 Expiration of reported stock option grant

Key Terms

Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares

4 terms

Rule 10b5-1 regulatory

"adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of $5.59 per share and expiration date March 1, 2034"

Ordinary Shares financial

"Ordinary Shares sold in open-market transactions and underlying the exercised stock options"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 11:00 PM Accepted by SEC EDGAR 07/02/2026 - 10:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abi-Saab Walid

(Last) (First) (Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM 1105BP

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/30/2026		M(1)		10,000	A	$5.59	178,235	D
Ordinary Shares	06/30/2026		S(1)		10,000	D	$46.46(2)	168,235	D
Ordinary Shares	06/30/2026		S(1)		20,000	D	$46.4(3)	148,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.59	06/30/2026		M(1)			10,000	(4)	03/01/2034	Ordinary Shares	10,000	$0	50,500	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

4. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.

	/s/ Christian Klemt, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did uniQure (QURE) Chief Medical Officer Walid Abi-Saab report in this Form 4?

He reported an exercise-and-sell sequence involving uniQure Ordinary Shares. On June 30, 2026, he exercised 10,000 stock options at $5.59 per share, then sold 30,000 Ordinary Shares in open-market transactions at weighted average prices of $46.40 and $46.46.

How many uniQure (QURE) shares did the CMO sell and at what prices?

Walid Abi-Saab sold 30,000 uniQure Ordinary Shares. The Form 4 reports two weighted average sale prices: $46.40 per share for 20,000 shares and $46.46 per share for 10,000 shares, with detailed trade breakdowns available on request from the issuer or the SEC staff.

What options did the uniQure (QURE) CMO exercise in this filing?

He exercised stock options covering 10,000 Ordinary Shares at a $5.59 exercise price. These options were granted on March 1, 2024, vesting 25% after one year and 6.25% quarterly thereafter, and are scheduled to expire on March 1, 2034 if unexercised.

How many uniQure (QURE) shares and options does the CMO hold after these transactions?

After the June 30, 2026 transactions, Walid Abi-Saab directly owns 148,235 uniQure Ordinary Shares. He also holds 50,500 stock options with an exercise price of $5.59 per share, which are scheduled to expire on March 1, 2034, according to the Form 4 disclosure.

Was the uniQure (QURE) CMO’s share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the reported transactions were effected under a sales plan adopted on September 26, 2025, intended to comply with Rule 10b5-1. Such pre-arranged trading plans schedule transactions in advance, reducing the significance of their exact timing as a discretionary decision.